GENEVA – Unitaid is pleased to present its 2016-2017 annual report, which describes a rewarding phase in the fight against the global epidemics of HIV/AIDS — including co-infections such as hepatitis C – and tuberculosis and malaria.
During the two years covered by the report, Unitaid launched a robust new operational strategy that supports the global push to end the three epidemics by 2030. At the same time, we awarded a spectrum of forward-looking grants designed to deploy the world’s best new technologies at the heart of the epidemics.
As Executive Board Chair Celso Amorim has commented, “At Unitaid, we do not pursue innovation for its own sake, but rather as a way to change outcomes in the real world.”
Throughout, Unitaid pursued its flagship projects—from bringing the best new HIV drugs to lower-resource countries to supporting the first new treatments for drug-resistant TB in nearly half a century.
The annual report also reflects our commitment to confront the threat posed by growing resistance to HIV, TB and malaria treatment, a phenomenon caused by misuse of medicines. Resistance threatens to undermine the extraordinary gains that have been made against the diseases over the past two decades. Unitaid has committed more than half its portfolio to projects to stop bacteria, viruses, fungi and parasites becoming resistant to antimicrobial drugs.
